| Literature DB >> 35565783 |
Franchek Drobnic1, Mª Antonia Lizarraga2, Alberto Caballero-García3, Alfredo Cordova4.
Abstract
Evidence exists to suggest that ROS induce muscular injury with a subsequent decrease in physical performance. Supplementation with certain antioxidants is important for physically active individuals to hasten recovery from fatigue and to prevent exercise damage. The use of nutritional supplements associated with exercise, with the aim of improving health, optimizing training or improving sports performance, is a scientific concern that not only drives many research projects but also generates great expectations in the field of their application in pathology. Since its discovery in the 1970s, coenzyme Q10 (CoQ10) has been one of the most controversial molecules. The interest in determining its true value as a bioenergetic supplement in muscle contraction, antioxidant or in the inflammatory process as a muscle protector in relation to exercise has been studied at different population levels of age, level of physical fitness or sporting aptitude, using different methodologies of effort and with the contribution of data corresponding to very diverse variables. Overall, in the papers reviewed, although the data are inconclusive, they suggest that CoQ10 supplementation may be an interesting molecule in health or disease in individuals without a pathological deficiency and when used for optimising exercise performance. Considering the results observed in the literature, and as a conclusion of this systematic review, we could say that it is an interesting molecule in sports performance. However, clear approaches should be considered when conducting future research.Entities:
Keywords: Coenzyme Q10; mitoquinone; nutritional supplement; ubiquinol; ubiquinone
Mesh:
Substances:
Year: 2022 PMID: 35565783 PMCID: PMC9104583 DOI: 10.3390/nu14091811
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Methodological quality of the studies included in the systematic review. Assessment of the methodological quality of studies using the PEDro Scale.
| References | Svensson | Díaz-Castro | Kizaki | Kon | Sarmiento | Suzuki | Braun | Ho | Weston |
|---|---|---|---|---|---|---|---|---|---|
| Criteria 1 * | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 4 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Criteria 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 7 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 8 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Criteria 9. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 10 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Criteria 11 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PEDro Score | 9 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 9 |
Criteria 1 * = The eligibility criterion is not scored for being related to external validity and therefore does not reflect the quality dimensions assessed by the PEDro Scale.
Figure 1Full search strategy. Eligibility criteria of the review: randomised, double-blind, placebo-controlled, parallel design, determining at least plasma CoQ10 levels, and that the human sample were athletes or subjects trained and used to practising high-intensity exercise.
Studies with the inclusion criteria.
| Reference | Molecule | CoQ10 | Duration (d: Days) | Placebo | n | Type of Subjects | Sex | Sport/Activity | Exercise Testing | Age (Years) | Impact on Phys./Sport Perf. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Svensson et al. (1999) | [ | Ubiquinone | 120 | 20 d | Yes | 17/9 | Well trained subjects | Male | - | Graded max and Anaerobic tests | 28 ± 5 | No |
| Díaz-Castro et al. (2020) | [ | Ubiquinol | 200 | 14 d | Yes | 100/50 | Well trained subjects | Male | Firemen | Circuit edurance exercises | 39 ± 1 | - |
| Kizaki et al. (2015) | [ | Ubiquinol | 600 | 11 d | Yes | 32/17 | Well trained subjects | Male | Kendo | 4 training days | 20 ± 1 | No |
| Kon et al. (2008) | [ | Ubiquinol | 300 | 20 d | Yes | 18/10 | High level | Male | Kendo | Muscle injury induced exercise | 20 ± 1 | Yes |
| Sarmiento et al. (2016) | [ | Ubiquinol | 200 | 14 d | Yes | 100/50 | Well trained subjects | Male | Firemen | Circuit edurance exercises | 39 ± 9 | - |
| Suzuki et al. (2021) | [ | Ubiquinol | 300 | 12 d | Yes | 16/8 | Well trained subjects | Male | Distance runners | 25 & 40 K races | 20 ± 2 | Yes |
| Braun et al. (1991) | [ | Ubiquinone | 100 | 56 d | Yes | 12/6 | High level | Male | Cyclists | Graded max test | 22 ± 2 | No |
| Ho et al. (2020) | [ | Ubiquinone | 300 | 84 d | Yes | 31/15 | Moderately trained subjects | Male & Female | Soccer & Taekwondo | None | 20 ± 1 | - |
| Weston et al. (1997) | [ | Ubiquinone | ≃70 | 28 d | Yes | 18/6 | High level | Male | Cyclists and Triathletes | Graded max. | 25 ± 3 | No |
Studies with the inclusion criteria.
| Reference | Change CoQ10 Total | Measured Parameters and Effects of CoQ10 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tissue | Plasma | Plasma | Muscle | Inflammatory Pattern | Antioxidant | Physical Performance | Sport Performance | Muscle Injury | Other | |
| Svensson et al. (1999) | Plasma ↑ Muscle ↔ | 0.74 ➝ 1.23 | 40.8 ➝ 44.2 mgl/kg | HX, MDA, UA ↔ | ||||||
| Díaz-Castro et al. (2020) | Plasma ↑ | 1.00 ➝ 5.22 | VEGF, NO, EGF, IL-1ra, IL-10 ↑, and IL-1, IL-8, MCP-1 ↓ | PTH, OC, OPG, phosphatase al., leptin, insulin, noradrenaline and PGC-1α ↑, | ||||||
| Kizaki et al. (2015) | Plasma↑ | 0.7 ➝ 10.8 | CK, Mb ↔, | |||||||
| Kon et al. (2008) | Plasma↑ | ≃0.8 ➝ ≃3.8 | LPO ↓ | CK, Mb ↓ | ||||||
| Sarmiento et al. (2016) | Plasma ↑ | 0.9 ➝ 4.5 | NO ↓ | hydroperoxydes Isoprostanes, oxidized LDL, TAC ↑ | ||||||
| Suzuki et al. (2021) | Plasma ↑ | 0.7 ➝ 5.6 | Perception of fatigue ↓ | CK, ALT, LDH ↓ | ||||||
| Braun et al. (1991) | Plasma ↑ | ≃0.8 ➝ 1.5 | MDA ↓ (NS) | Total work load, VO2peak, HR ↔ | CoQ10 postexercise ↑ | |||||
| Ho et al. (2020) | Plasma ↑ | 0.57 ➝ 1.14 | 130 ➝ 270 | MDA ↓, TAC ↔ | Improve glycemic control | |||||
| Weston et al. (1997) | Plasma ↑ | 0.9 ➝ 2.0 | Oxygen uptake at 6 min ↑, VO2max, max power, Anaerobic threshold, and HRTime ↔ | |||||||
CoQ10/Chol: CoQ10 in relation to cholesterol level; pre/post: previous and post supplementation; Ns: No specified; Phys. Physical; Perf: Performance; ↔ similar response to placebo or previous supplementation, ↑ Higher response to the presupplementation phase, ↓ Lower response to the presupplementation phase. HX hypoxanthine, MDA malondyaldehide, UA uric acid, PTH parathormone, OC osteocalcin, OPG osteoprotegerin, PGC-1α peroxisome proliferator activated receptor-γ coactivator-1α VEGF vascular endothelial growth factor, NO nitric oxide, EGF epidermal growth factor, CK creatinkinase, Mb myoglobin, ALT alanine transaminase, LDH lactate dehydrogenase, TAC Total antioxidant capacity, MCP-1 monocyte chemotactic protein, LPO lipid peroxidation.
Studies without the inclusion criteria.
| Reference | Molecule | CoQ10 | Duration (d: Days) | Placebo | n | Type of Subjects | Sex | Sport/Activity | Exercise Testing | Age (Years) | Impact on Phys./Sport Perf. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alf et al. (2013) | [ | Ubiquinol | 300 | 42 d | Yes | 100/50 | High level | Male & Female | Olympic Athletes | Cycling submaximal test | 19 ± 3 | Yes/Yes |
| Bloomer et al. (2012) | [ | Ubiquinol | 300 | 28 d | Yes | 15/15 | Well trained subjects | Male & Female | Ns | Graded and Anaerobic max. Tests | 43 ± 10 | No |
| Kunching et al. (in press) | [ | Ubiquinol | 200 | 42 d | Yes | 29/15 | Moderately trained subjects | Male | Diverse | Indirect max. Test, 1RM and flexibility | 24 ± 2 | Yes |
| Orlando et al. (2018) | [ | Ubiquinol | 200 | 28 d | Yes | 21/21 | Moderately trained subjects | Male | Rugby | 40 min 85%max. Treadmill | 26 ± 5 | No |
| Pham et al. (2020) | [ | Ubiquinol | 200 | 42 d | No | 22/22 | Physically active subjects | Male | - | None | 51 ± 1 | - |
| Broome et al. (2021) | [ | Mitoquinone | 20 | 28 d | Yes | 19/19 | Well trained subjects | Male | Cyclists | 8 km race | 44 ± 4 | Yes |
| Pham et al. (2020) | [ | Mitoquinone | 20 | 42 d | No | 22/22 | Physically active subjects | Male | - | None | 51 ± 1 | - |
| Shill et al. (2021) | [ | Mitoquinone | 10 | 21 d | Yes | 20/10 | Physically active subjects | Male | - | Graded max test | 22 ± 1 | No |
| Williamsom et al. (2020) | [ | Mitoquinone | 20 | 21 d | Yes | 24/12 | Physically active subjects | Male | - | Anaerobic repeated tests | 25 ± 4 | Yes |
| Amadio et al. (1991) | [ | Ubiquinone | 100 | 40 d | Control | 10/5 | Well trained subjects | Male | Basketball | Submaximal test | 19 ± 5 | Yes |
| Armanfar et al. (2015) | [ | Ubiquinone | 300–400 | 14 d | Yes | 18/9 | Well trained subjects | Male | Middle distance runners | 3000 m race | 20 ± 3 | No |
| Bonetti et al. (2000) | [ | Ubiquinone | 100 | 56 d | Yes | 28/14 | Moderately trained subjects and NA | Male | Cyclists | Graded max test | 41 ± 6 | Yes |
| Cerioli (1991) | [ | Ubiquinone | 100 | 30 d | Ns | 12 | Non active | Male | - | Graded max test | 26 | Yes |
| Cinquegrana et al. (1987) | [ | Ubiquinone | 60 | 35 d | Yes | 14/14 | Non active | Male | - | Graded max test | 48 ± 3 | |
| Ciocoi-Pop et al. (Note I & II) (2009) | [ | Ubiquinone | 30 | 21 d | Yes | 10/5 | Well trained subjects | Male | Soccer | Graded max and Anaerobic tests | 19 ± 0 | Yes |
| Cooke et al. (2008) | [ | Ubiquinone | 200 | 14 d | Yes | 31/21 | Moderately trained subjects and untrained | Male & Female | - | Grade max, Isokinetic, and Anaerobic tests | 26 ± 8 | No |
| Díaz-Castro et al. (2012) | [ | Ubiquinone | 30 × 2 days, 120 day test | 3 d | Yes | 20/10 | Well trained subjects | Male | - | 50 km running | 41 ± 3 | Yes |
Studies without the inclusion criteria.
| Reference | Change CoQ10 Total | Measured Parameters and Effects of CoQ10 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tissue | Plasma | Plasma | Muscle | Inflammatory Pattern | Antioxidant | Physical Performance | Sport Performance | Muscle Injury | Other | |
| Alf et al. (2013) | - | Power output ↑ | ||||||||
| Bloomer et al. (2012) | Plasma ↑ | 0.98 ➝ 2.33 | 0.48 ➝ 1.13 | MDA, hydrogen peroxide, | Lactate ↔ | perceived vigour ↔ | ||||
| Kunching et al. (in press) | - | VO2max ml/kg ↑,Max strength ↔ | Sistolic pressure ↓ | |||||||
| Orlando et al. (2018) | Plasma ↔ | ≃180 ➝ >500 | ROS ↓ | Time to exhaustion, speed ↔ | CK, DNA damage ↔ | |||||
| Pham et al. (2020) | - | H2O2 mit ↓, Isoprost ↔ | ||||||||
| Broome et al. (2021) | - | ROS, Isoprost ↓ | Power output ↑ | Faster time trial. | ||||||
| Pham et al. (2020) | - | H2O2 mit ↓, TAC ↑, Isoprostanes ↔ | ||||||||
| Shill et al. (2021) | - | CDseries, VEGFR2+ and peripheral blood mononuclear cells ↔ | VO2max ↔ | Muscle mitochondrial capacity ↔ | ||||||
| Williamsom et al. (2020) | - | DNA damage ↓ | ||||||||
| Amadio et al. (1991) | Plasma ↑ | 0.9 ➝ 1.6 | VO2max ↑ | Cardiac parameters | ||||||
| Armanfar et al. (2015) | - | TNFa, CRP, IL6 ↓ | CK ↔ | |||||||
| Bonetti et al. (2000) | Plasma ↑ | 0.8 ➝ 2.2 | hypoxanthine, xanthine and inosine ↔ | Max work load ↑ VO2peak, anaerobic threshold and lactate ↔, | ||||||
| Cerioli (1991) | - | Aerobic Capacity↑ | CK ↔ | FFA ↓,Fat metabolism ↑ | ||||||
| Cinquegrana et al. (1987) | - | |||||||||
| Ciocoi-Pop et al. (Note I&II) (2009) | - | MDA ↑, HD ↑ in saliva | VO2max ↑, Anaerobic power ↔ | |||||||
| Cooke et al. (2008) | Plasma ↑ | ≃0.6 ➝ ≃2.5 | ≃1.2 ➝ ≃1.4 | MDA ↑, SOD ↓ | VO2max, anaerobic capacity, Anaerobic power ↔ | |||||
| Díaz-Castro et al. (2012) | - | IL-6 ↔, 8-OH-dG, TNF-α ↓ | CAT ↑, TAS ↑, GPx ↔, hydroperoxide ↓, isoprostane ↓, | |||||||
CoQ10/Chol: CoQ10 in relation to cholesterol level; pre/post: previous and post supplementation; Ns: No specified; Phys. Physical; Perf: Performance; ↔ similar response to placebo or previous supplementation, ↑ Higher response to the presupplementation phase, ↓ Lower response to the presupplementation phase. GPx Glutathione peroxidase, MDA malondyaldehide, ROS reactive oxygen species, CK creatinquinase, VO2 oxygen consumption, HD hydrogen donors, SOD superoxide dismutase, CAT catalase, TAS Plasma total antioxidant status, 8-OH-dG 8-Hydroxy-20-deoxyguanosine, TNF-α Tumor necrosis factor a, FFA free fatty acids, CRP C-reactive protein, IL6 interleukin 6.
Studies without the inclusion criteria.
| Reference | Molecule | CoQ10 | Duration (d: Days) | Placebo | n | Type of Subjects | Sex | Sport/Activity | Exercise Testing | Age (Years) | Impact on Phys./Sport Perf. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drobnic et al. (2020) | [ | Ubiquinone | 100 | 30 d | Control | 20/12 | Well trained subjects | Male | Marathon runners | Treadmill Hot & Humid environment | 55 ± 4 | Yes |
| Emami et al. (2018) | [ | Ubiquinone | 300 | 14 d | Yes | 36/9 | Well trained subjects | Male | Swimmwers | Swimming training | 18 ± 1 | |
| Fiorella et al. (1991) | [ | Ubiquinone | 100 | 40 d | Control | 22/11 | Well trained subjects | Male | Athletes | Graded max test + Incremental running test until exhaustion | 29 ± 6 | Yes |
| García-Verazaluce et al. (2015) | [ | Ubiquinone + | 120 + Phlebodium d. | 28 d | Yes | 30/10 | Well trained subjects | Male | Volleyball | None | 25 ± 2 | Ns |
| Geiss et al. (2004) | [ | Ubiquinone | 180 | 28 d | Yes | 10/10 | Well trained subjects | Male? | Endurance | Submaximal fatigue test | Ns | Yes |
| Gökbel et al. (2010) | [ | Ubiquinone | 100 | 56 d | Yes | 15/15 | Non active | Male | Ns | Anaerobic test(Repeated Wingate test) | 20 ± 1 | No |
| Gökbel et al. (2016) | [ | Ubiquinone | 200 | 98 d | Yes | 23/23 | Patients (hemodyalisis) | Male | Ns | 6 Mins walking test | 47 ± 12 | No |
| Guerra et al. (1987) | [ | Ubiquinone | 60 | 35 d | Ns | Moderately trained subjects | Male | Cycling | Graded max test. Race 9 km. | Ns | Yes/Yes | |
| Gül et al. (2011) | [ | Ubiquinone | 100 | 56 d | Yes | 15 | Non active | Male | - | Anaerobic repeated tests | 20 ± 1 | Yes |
| Kaikkonen et al. (1998) | [ | Ubiquinone | 90 + Vit E | 21 d | Yes | 37/18 | Moderately trained subjects | Male | Marathon | Marathon | 40 ± 7 | No |
| Laaksonen et al. (1995) | [ | Ubiquinone | 120 + | 42 d | Yes | 11/11 | Well trained subjects | Male | Marathon & triathletes | Graded max. test | 28 | No |
| 8/8 | 64 | No | ||||||||||
| Leelarungrayub (2010) | [ | Ubiquinone | 300 | 12 d | No | 16/16 | Moderately trained subjects | Male & Female | Swimmimg | Treadmill time to exhaustion & Swimmimg 100–800 m | 15 ± 1 | Yes 100 m, |
| Malm et al. (1996) | [ | Ubiquinone | 120 | 20 d | Yes | 15/9 | Moderately trained subjects | Male | - | Anaerobic tests | 20–34 | No |
| Malm et al. (1997) | [ | Ubiquinone | 120 | 22 d | Yes | 18/9 | Moderately trained subjects | Male | - | Graded max and Anaerobic tests | 25 ± 3 | No |
| Mizuno et al. (2008) | [ | Ubiquinone | 100 & 300 | 56 d | Yes | 17/17 | Physically active subjects | Male & Female | - | Anaerobic repeated tests under fatigue | 38 ± 10 | Yes |
| Nielsen et al. (1999) | [ | Ubiquinone | 100 + Vit E & Vit C | 42 d | Yes | 7/7 | Well trained subjects | Male | Triathletes | Graded max. & Local fatigue (31P-NMRS) | 22–32 | No |
+: indicates that the administration of Ubiquinone is supplemented by one or more other substances (indicated in the next column).
Studies without the inclusion criteria.
| Reference | Change CoQ10 Total | Measured Parameters and Effects of CoQ10 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tissue | Plasma | Plasma | Muscle | Inflammatory Pattern | Antioxidant | Physical Performance | Sport Performance | Muscle Injury | Other | |
| Drobnic et al. (2020) | Plasma ↑ Muscle ↑ | 1.11 ➝ 2.34 | 212 ➝ 476 | 245 ➝ 299nmol/g protein | IL-6, IL-8, IL-10, MCP-1, TNFa ↓ | MDA ↓, TAC ↑ after exercise | Lactate and fatigue perception ↑, | |||
| Emami et al. (2018) | Plasma ↑ | ≃0.8 ➝ ≃2.5 | TAC ↑, LPO ↓, | LDH, CK-MB, Mb, Troponin I ↓ | ||||||
| Fiorella et al. (1991) | Plasma ↑ Thrombocites↑ | 0.6 ➝ 1.4 37.5➝61.8 | LA, UA, Ammonia ↔ | Running distance and time to exhaustion ↑, | CK, LDH ↓, | |||||
| García-Verazaluce et al. (2015) | - | IL6 ↓ | Costisol ↓ | |||||||
| Geiss et al. (2004) | Plasma ↑ | 0.6 ➝ 1.7 | Power output ↑ | |||||||
| Gökbel et al. (2010) | - | Peak Power ↔, Mean Power ↑, Fatigue Index ↔ | ||||||||
| Gökbel et al. (2016) | Plasma ↑ | 1.3 ➝ 3.0 | MDA ↓, GPX↓, SOD ↔, after exercise (NS) | |||||||
| Guerra et al. (1987) | Plasma ↑ | Ns | VO2max ↑ | Possible better race time | ||||||
| Gül et al. (2011) | - | MDA ↓, NO, XO, SOD, GPx ↔, UA ↑ | ||||||||
| Kaikkonen et al. (1998) | Plasma ↑ | 1.96 ➝ 2.03 | GSH, UA, LDLox, TRAP ↔ | |||||||
| Laaksonen et al. (1995) | Plasma ↑ | 0.9 ➝ 2.0 | 118 ➝ 128 | MDA ↔ | VO2max ↔, Time to exhaustion | |||||
| Plasma ↑ | 1.31 ➝ 3.5 | 92 ➝ 78 | ||||||||
| Leelarungrayub et al. (2010) | Plasma ↑ | 1.1 ➝ 2.3 | MDA, NO ↓, | Increase time to fatigue | No better 800 m swimming time | |||||
| Malm et al. (1996) | - | CK ↑ | ||||||||
| Malm et al. (1997) | - | ROS ↑ | VO2max ↔, Max power ↔ | |||||||
| Mizuno et al. (2008) | Plasma ↑ | 100 mg. 0.5 ➝ 2.0 | Perception of fatigue ↓, Perception of recovery, Max velocity ↑ | |||||||
| Nielsen et al. (1999) | Plasma ↑ | 0.9 ➝ 1.8 | VO2max ↔ | Muscle metabolism ↔ | ||||||
CoQ10/Chol: CoQ10 in relation to cholesterol level; pre/post: previous and post supplementation; ➝: Concentration change; Ns: No specified, Phys. Physical; Perf: Performance; ↔ similar response to placebo or previous supplementation, ↑ Higher response to the presupplementation phase, ↓ Lower response to the presupplementation phase, NS: Non statistical significance. MDA malondyaldehide, TAC total antioxidant capacity, LPO lipid peroxidation, LDH lactate dehydrogenase, CK-MB miocardic creatinquinase, Mb myoglobin, LA lactic acid, UA uric acid, CK creatinquinase, SOD superoxide dismutase, NO nitric oxide.
Studies without the inclusion criteria.
| Reference | Molecule | CoQ10 | Duration (d: Days) | Placebo | n | Type of Subjects | Sex | Sport/Activity | Exercise Testing | Age (Years) | Impact on Phys./Sport Perf | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Okudan et al. (2017) | [ | Ubiquinone | 200 | 28 d | Yes | 21/11 | Non active | Male | - | Exccentric ex. | 23 ± 0 | No |
| Östman et al. (2012) | [ | Ubiquinone | 90 | 56 d | Yes | 23/11 | Moderately trained subjects | Male | - | Various exercise capacity tests | 28 ± 9 | No |
| Porter et al. (1995) | [ | Ubiquinone | 150 | 56 d | Yes | 13/6 | Physically active subjects | Male | Some with hypertension | Graded Max and Forearm Handgrip tests | 45 ± 2 | Yes |
| Snider et al. (1992) | [ | Ubiquinone + | 100 + Vit E, C inosine, citochrome C | 28 d | Yes | 11/11 | High level | Male | Triathletes | Graded max. test | 25 ± 1 | No |
| Tauler et al. (2008) Ferrer et al. (2009) | [ | Ubiquinone + | 100+ Multivitamin | 90 d | Yes | 19/8 | High level | Male | Soccer | Competition Match | 20 ± 0 | Yes |
| Vanfraechem et al. (1981) | [ | Ubiquinone | 60 | 56 d | Yes | 6 | Non active | Male | None | Graded max. 4w–8w | 22 ± 2 | Yes |
| Wyss et al. (1990) | [ | Ubiquinone | 100 | 30 d | Yes | 18/18 | Physically active subjects | Male | Running | Graded max. | 25 ± 4 | Yes |
| Yamabe et al. (1991) | [ | Ubiquinone | 90 | 6 months | No | 9/9 | Non active with inabilities to do exercise | Male | - | Graded max. | 51 ± 5 | Yes |
| Ylikoski et al. (1997) | [ | Ubiquinone | 90 | 42 d | Yes | 18/18 | High level | Male | cross-country skiers | Graded max. | Ns | Yes |
| Zeppilli et al. (1991) | [ | Ubiquinone | 100 | 30 d | Yes | 9/9 | High level | Male | Volleyball | Graded max test | 17–2 | Yes |
| 10 | Non active | - | 23–29 | Yes | ||||||||
| 8 | Patients | Mit. Disease | 23–29 | Yes | ||||||||
| Zheng et al. (2008) | [ | Ubiquinone | 30 | 1d | Yes | 11/11 | Non active | Male | - | Rest & Low intensity exercise (30% HRmax) | 26 ± 1 | Yes |
| Zhou et al. (2005) | [ | Ubiquinone + | 150+ Vit E | 14 d | Yes | 6/6 | Physically active subjects | Male | - | Submaximal exercise and Graded max tests | 30 ± 7 | No |
| Zuliani et al. (1989) | [ | Ubiquinone | 100 | 28 d | No | 12 | Non active | Male | - | 60’ ciloergometry | 26 | No |
| Sanchez-Cuesta et al. (2020) | [ | . | - | 2 Sport seasons | - | 24 & 25 | High level | Male | Soccer | Weekly competition | 26 ± 4 | Yes |
+: indicates that the administration of Ubiquinone is supplemented by one or more other substances (indicated in the next column).
Studies without the inclusion criteria.
| Reference | Change CoQ10 Total | Measured Parameters and Effects of CoQ10 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tissue | Plasma | Plasma | Muscle | Inflammatory Pattern | Antioxidant | Physical Performance | Sport Performance | Muscle Injury | Other | |
| Okudan et al. (2017) | Plasma ↑ | 1.0 ➝ 1.7 | MDA, SOD ↔ | CK, Myogb. ↔ | ||||||
| Östman et al. (2012) | - | MDA, UA, hypoxanthine ↔ | Exercise capacity, VO2max, Max power, Lactate ↔ | CK, UA ↔ | ||||||
| Porter et al. (1995) | Plasma ↑ | 0.7 ➝ 1.0 | VO2max ↔ LA ↓(NS) | Vigor perception ↑ | ||||||
| Snider et al. (1992) | - | Time to exhaustion, | ||||||||
| Tauler et al. (2008) Ferrer et al. (2009) | Plasma ↑ | 3.0 ➝ 3.6 | SOD ↑, MDA ↓ | ↑ Time spend in active working zone (Z3-Z5) | ||||||
| Vanfraechem et al. (1981) | - | Maximal load and O2 consumption 170 w and max. | Cardiaovascular and cardiorespiratory parameters ↑ | |||||||
| Wyss et al. (1990) | Plasma ↑ | Ns | VO2max ↑, Max work ↑, | |||||||
| Yamabe et al. (1991) | - | VO2max, Max power and Anaerobic threshold ↑ | ||||||||
| Ylikoski et al. (1997) | Plasma ↑ | 0.8 ➝ 2.8 | VO2max, max power, Anaerobic threshold, and HRTime↑ | |||||||
| Zeppilli et al. (1991) | Plasma ↑ | 0.6 ➝ 1.3 Vb 0.7 ➝ 1.0 NA | VO2max, max power ↑ | |||||||
| Zheng et al. (2008) | - | VCO2/VO2 ↓, HR ↔ | ↑ Power HR variability | |||||||
| Zhou et al. (2005) | Plasma↑, Muscle ↔ | 0.8 ➝ 2.6 | 207 ➝ 220 | VO2max ↔, HR ↔, RPE ↔, Anaerobic threshold ↔ | ||||||
| Zuliani et al. (1989) | Plasma ↑ | 0.5 ➝ 1.3 | Glucose, Insulin, LA ↔ | CK ↔, | Glycerol ↔, FFA ↓ | |||||
| Sanchez-Cuesta et al. (2020) | Plasma ↑ | Preseason 0.6 Middle season 0.9 | The highest values have better competition parameters | CK ↓ | Better Testosterone/cortisol pattern | |||||
CoQ10/Chol: CoQ10 in relation to cholesterol level; pre/post: previous and post supplementation; Ns: No specified; Phys. Physical; Perf: Performance; ↔ similar response to placebo or previous supplementation, ↑ Higher response to the presupplementation phase, ↓ Lower response to the presupplementation phase, NS: Non statistical significance. The study of Sanchez-Cuesta as it is explained in the text, is the follow up of the CQ10 plasma level throughout 2 competition seasons. Vb volleyball, NA No physical activity, HR heart rate, RPE rating perceived perception.
Results of the Ubiquinone and Ubiquinol supplementation on different sport and exercise variables depending on the physical condition of the subjects evaluated.
| Physical Condition Categories | Number of Studies | CoQ10 | Total | Sport | Exercise | Oxidative | Muscle | Inflammatory | Other |
|---|---|---|---|---|---|---|---|---|---|
| High level/Well trained athletes | 28 | Positive | 39 | 3 | 12 | 10 | 4 | 6 | 4 |
| No effect | 12 | 6 | 1 | 3 | 1 | 1 | |||
| Moderate trained/Physically active | 20 | Positive | 11 | 4 | 5 | 1 | 2 | ||
| No effect | 18 | 1 | 9 | 5 | 3 | ||||
| Negative | 3 | 2 | 1 | ||||||
| Non active | 9 | Positive | 11 | 6 | 1 | 4 | |||
| No effect | 4 | 2 | 2 | ||||||
| Patients | 1 | Positive | 2 | 1 | 1 | ||||
| TOTAL | 58 | number tests | 100 * | 3 | 40 | 25 | 14 | 7 | 11 |
| Positive | 63 | 2 | 23 | 17 | 5 | 6 | 10 | ||
| No effect | 34 | 1 | 17 | 6 | 8 | 1 | 1 | ||
| Negative | 3 | 2 | 1 |
* In the Zeppilli research [77] there are three populations (<30 a) that are studied with the same methodology. That is the reason why there are 2 more tests than in Table 11.
Results of the Ubiquinone and Ubiquinol supplementation on different sport and exercise variables depending on the age categories of the subjects evaluated.
| Age | Number of Studies | CoQ10 | Total | Sport | Exercise | Oxidative | Muscle | Inflammatory Pattern | Other |
|---|---|---|---|---|---|---|---|---|---|
| <30 | 37 | Positive | 38 | 2 | 12 | 9 | 5 | 2 | 8 |
| No effect | 26 | 1 | 13 | 3 | 7 | 1 | 1 | ||
| Negative | 3 | 2 | 1 | ||||||
| 31–50 | 11 | Positive | 15 | 1 | 3 | 6 | 3 | 2 | |
| No effect | 6 | 3 | 2 | 1 | |||||
| >50 | 7 | Positive | 5 | 2 | 2 | 1 | |||
| No effect | 2 | 1 | |||||||
| No specified | 3 | Positive | 3 | 3 |
Recommended methodological guidelines for a future study on human physical performance of CoQ10.
| Physical activity: | Four types: No physically active or light activity (<3 d/week), Moderately active (3–5 d/week), Very active (5–7 d/week), High level athletes. |
| Age (years): | Four types: ≤33, 34–48, 49–64, ≥65 |
| Diet: | Homogenise the sample according to the type of diet |
| Dosage | 4.0–4.5 mg/kg/d of Ubiquinol or Ubiquinone with Phytosome or Ubiquinone with vehicle to increase bioavailability, or explaining perfectly the diet related to the administration. |
| Placebo | Yes, double blinded. |
| Type of study | Parallel, never crossover to avoid training and supplementation effect |
| Tissue concentration (plasma) | Mandatory. Always after 24 h after last doses of placebo or study substance. |
| Tissue concentration (muscle) | Very recommended. |
| Treatment period | >1 week. |
| Effort test before and after supplementation | Characterization of the maximal oxygen consumption of every subject by a graded maximal exercise test. |